| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced that its positive Phase 2a clinical trial data and biomarker results were featured in two presentations, including a Featured Research Session oral presentation, at the Alzheimer’s Association International Conference® (AAIC), taking place July 28 – August 1, 2024, in Philadelphia and online.
“As a medicinal signaling cell therapy that has multiple potential mechanisms of action to address inflammatory responses in the brain, Lomecel-B™ offers potential to address the underlying pathology of Alzheimer’s Disease without the limitations of previous therapies,” said Wa’el Hashad, Chief Executive Officer at Longeveron. “We are very encouraged by the safety profile and efficacy evidence that support the differentiated therapeutic potential of Lomecel-B™ and lay the foundation for its future clinical development. We’re pleased to connect with the Alzheimer’s community at AAIC 2024 and contribute to the growing body of evidence that fuels the continued development of novel therapeutics for this devastating disease.”
Posted In: LGVN
